{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:56:45Z","timestamp":1696294605359},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Natural Science General Program Foundation of China","award":["81170510"],"award-info":[{"award-number":["81170510"]}]},{"name":"Major Program Foundation of China","award":["81090410"],"award-info":[{"award-number":["81090410"]}]}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.leukres.2013.08.019","type":"journal-article","created":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T02:47:27Z","timestamp":1378435647000},"page":"1583-1591","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment"],"prefix":"10.1016","volume":"37","author":[{"given":"Hongju","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqiang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yani","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianxiang","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.08.019_bib0005","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.08.019_bib0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR-ABL oncogene","volume":"40","author":"Sattler","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2013.08.019_bib0015","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2013.08.019_bib0020","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1007\/s002800100310","article-title":"a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy","volume":"48","author":"Mauro","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2013.08.019_bib0025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2002-02-0545","article-title":"Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.08.019_bib0030","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.leukres.2003.08.002","article-title":"Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase","volume":"28","author":"Moravcova","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.08.019_bib0035","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review","volume":"34","author":"An","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.08.019_bib0040","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.leukres.2013.08.019_bib0045","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.08.019_bib0050","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13238-011-1089-z","article-title":"CUEDC2: an emerging key player in inflammation and tumorigenesis","volume":"2","author":"Man","year":"2011","journal-title":"Protein Cell"},{"key":"10.1016\/j.leukres.2013.08.019_bib0055","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/ncb2287","article-title":"Cdk1-phosphorylated CUEDC2 promotes spindle checkpoint inactivation and chromosomal instability","volume":"13","author":"Gao","year":"2011","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.leukres.2013.08.019_bib0060","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/sj.emboj.7601602","article-title":"CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin\u2013proteasome","volume":"26","author":"Zhang","year":"2007","journal-title":"EMBO J"},{"key":"10.1016\/j.leukres.2013.08.019_bib0065","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/bcr2914","article-title":"Estrogen receptor degradation: a CUE for endocrine resistance?","volume":"13","author":"Musgrove","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.leukres.2013.08.019_bib0070","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nm.2369","article-title":"Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer","volume":"17","author":"Pan","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2013.08.019_bib0075","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/ni.1600","article-title":"Deactivation of the kinase IKK by CUEDC2 through recruitment of the phosphatase PP1","volume":"9","author":"Li","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.leukres.2013.08.019_bib0080","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1074\/jbc.M111.276832","article-title":"CUEDC2 (CUE domain-containing 2) and SOCS3 (suppressors of cytokine signaling 3) cooperate to negatively regulate Janus kinase 1\/signal transducers and activators of transcription 3 signaling","volume":"287","author":"Zhang","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2013.08.019_bib0085","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.08.019_bib0090","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.08.019_bib0095","first-page":"337","article-title":"Establishment of an imatinib resistant cell line K562\/G01 and its characterization","volume":"25","author":"Qi","year":"2004","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.leukres.2013.08.019_bib0100","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/j.yexcr.2011.05.026","article-title":"NHE1 mediates MDA-MB-231 cells invasion through the regulation of MT1-MMP","volume":"317","author":"Lin","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.leukres.2013.08.019_bib0105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.cdd.4400476","article-title":"Emerging roles of caspase-3 in apoptosis","volume":"6","author":"Porter","year":"1999","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.leukres.2013.08.019_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BST0360001","article-title":"Caspase activation cascades in apoptosis","volume":"36","author":"Logue","year":"2008","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.leukres.2013.08.019_bib0115","first-page":"167","article-title":"Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy","volume":"1805","author":"Li","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.leukres.2013.08.019_bib0120","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1517\/14728222.2010.522570","article-title":"NF-kappaB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia","volume":"14","author":"Breccia","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.leukres.2013.08.019_bib0125","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/sj.leu.2402641","article-title":"Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts","volume":"16","author":"Baumgartner","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.08.019_bib0130","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ijc.24294","article-title":"NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants","volume":"125","author":"Lounnas","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.leukres.2013.08.019_bib0135","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.it.2008.07.003","article-title":"New insights into NF-kappaB regulation and function","volume":"29","author":"Sun","year":"2008","journal-title":"Trends Immunol"},{"key":"10.1016\/j.leukres.2013.08.019_bib0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.08.019_bib0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.leu.2403998","article-title":"The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance","volume":"20","author":"Cilloni","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.08.019_bib0150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00003495-200767020-00010","article-title":"Imatinib: a review of its use in chronic myeloid leukaemia","volume":"67","author":"Moen","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.leukres.2013.08.019_bib0155","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1101\/gad.12.7.968","article-title":"A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation","volume":"12","author":"Reuther","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.leukres.2013.08.019_bib0160","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0301-472X(03)00069-9","article-title":"Mechanisms of Bcr-Abl-mediated NF-kappaB\/Rel activation","volume":"31","author":"Kirchner","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2013.08.019_bib0165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14728220903431069","article-title":"The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy","volume":"14","author":"Lin","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.leukres.2013.08.019_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevOncog.v15.i1-2.10","article-title":"Nuclear Factor-kappaB Signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia","volume":"15","author":"Reikvam","year":"2009","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.leukres.2013.08.019_bib0175","doi-asserted-by":"crossref","DOI":"10.1007\/s10495-013-0854-2","article-title":"Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-kappaB inhibition and Bcr\/Abl protein deletion","author":"Wei","year":"2013","journal-title":"Apoptosis"},{"key":"10.1016\/j.leukres.2013.08.019_bib0180","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood-2002-01-0151","article-title":"Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells","volume":"100","author":"Mori","year":"2002","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613003159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613003159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T08:20:39Z","timestamp":1596442839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613003159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0145212613003159"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.08.019","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2013.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}